Rutgers University professor testifies in support of bill directing the FDA to designate National Centers of Excellence in Continuous Manufacturing; other bills target generic labeling, orphan exclusivity and counterfeit devices.
While brand name companies are adopting continuous manufacturing, others are struggling with the cost and knowledge required for implementation, Rutgers University professor Fernando Muzzio testified at a congressional hearing.
Speaking before the House Energy & Commerce Health Subcommittee on 24 January, Muzzio voiced support for H.R. 4866, the National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act. Introduced in...
President Trump’s new Executive Order on drug pricing reprises several policy themes from his first administration, including giving the FDA many tasks intended to increase competition in the marketplace.
Deputy FDA Commissioner Grace Graham acknowledged the importance of user fees, while also calling for restructuring. She also said part of MAHA's mission is to reexamine uses of drugs not supported by data.
At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.
As the US FDA expands unannounced foreign inspections building on pilots in India and China, experts expect higher scrutiny of overseas sites and perhaps even an industry shakeout in the longer term, though staffing and enforcement challenges could slow things down.
